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Background: Consensus exists that several bariatric surgery procedures produce a rapid improvement of glucose
homeostasis in obese diabetic patients, improvement apparently uncorrelated with the degree of eventual weight
loss after surgery. Several hypotheses have been suggested to account for these results: among these, the anti-
incretin, the ghrelin and the lower-intestinal dumping hypotheses have been discussed in the literature. Since no
clear-cut experimental results are so far available to confirm or disprove any of these hypotheses, in the present
work a mathematical model of the glucose-insulin-incretin system has been built, capable of expressing these three
postulated mechanisms. The model has been populated with critically evaluated parameter values from the
literature, and simulations under the three scenarios have been compared.
Results: The modeling results seem to indicate that the suppression of ghrelin release is unlikely to determine
major changes in short-term glucose control. The possible existence of an anti-incretin hormone would be
supported if an experimental increase of GIP concentrations were evident post-surgery. Given that, on the contrary,
collected evidence suggests that GIP concentrations decrease post-surgery, the lower-intestinal dumping
hypothesis would seem to describe the mechanism most likely to produce the observed normalization of Type 2
Diabetes Mellitus (T2DM) after bariatric surgery.
Conclusions: The proposed model can help discriminate among competing hypotheses in a context where
definitive data are not available and mechanisms are still not clear.
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Severe obesity is one of the major problems of modern
society, being related with a wide spectrum of diseases
(e.g. cardiovascular disease, metabolic syndrome, type 2
diabetes, certain kind of tumors [1-3] and increased
mortality. This problem has been expanding in recent
years, quadrupling from 1968 to 2000, reaching now al-
most 5% of the adult population. At present the most ef-
fective and long-lasting solution for clinically severe
obesity is bariatric surgery, which produces weight loss
between 50% and 75% of excess body weight. Compared
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reproduction in any medium, provided the orwith bariatric surgery the objective is typically main-
tained [4].
One of the main diseases linked to obesity is Type 2
Diabetes Mellitus (T2DM). The term “diabesity” [5] has
in fact been introduced to refer to obesity accompanied
by T2DM. As a consequence, it is not rare that subjects
undergoing bariatric surgery are affected by diabetes. In
such cases a very interesting side-effect of surgery has
been observed since the ‘70s, that is, T2DM remission.
This effect is already apparent few days after surgery, i.e.
much earlier than the beginning of weight loss.
The improvement of glycemia in post-bariatric-surgery
patients has been linked with an early improvement of
insulin resistance post-surgery [6,7]. On the other hand,
improvement in insulin secretion has also been proposed
[8]. Further, it is not really clear whether the improve-
ment in insulin resistance is immediate [6] or delayed by
a few months [9], and whether it could as well be
obtained by a very strict dietary regimen [10]. Therel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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publications on the topic.
A study by Muscelli et al. showed insulin sensitivity
amelioration proportional to weight loss after restrictive
procedures, while complete reversion of insulin sensitiv-
ity long before body weight normalization was observed
with malabsorptive surgery [11]. In 2006, Guidone et al.
published a study on 10 patients, in which diabetes com-
pletely disappeared one week after surgery and insulin
sensitivity was normalized [12]. Possible mechanisms
implicated in this phenomenon, such as incretins [13] or
ghrelin [14] have been discussed. Normalization of insu-
lin sensitivity after malabsorptive bariatric surgery could
be linked with the reduction of the effect of some intes-
tinal factors due to intestinal bypass [15]. Diabetes re-
mission after bariatric surgery can be key factor in the
development of diabetes treatment strategies, but the
underlying physiology, at present, is incompletely known
[16,17].
Therefore, mechanisms underlying insulin resistance
remission are still not clear: several hypotheses have
been proposed but none of them has been confirmed
yet.
There are several types of bariatric surgery procedures,
grouped in three main classes: restrictive bariatric sur-
gery, malabsorptive procedures and a combination of
the two. Restrictive bariatric surgery consists in reducing
the stomach size, thus increasing satiety and reducing
food intake. The most common such procedure is lap-
aroscopic adjustable gastric banding (GB). Malabsorptive
procedures are based on bypassing a portion of the gut,
thus consistently reducing the absorption of nutrients.
Biliopancreatic diversion (BPD) is the classical example
of malapsorptive procedure. However, the most common
type of bariatric surgery is Roux-en-Y gastric bariatric
procedure (RYGB), a combination restrictive and malab-
sorptive technique. In this kind of surgery the stomach
is reduced to a small proximal pouch, which is then ana-
stomosed to the jejunum, while the rest of the stomach
and the duodenum are bypassed, and reconnected to the
jejunum allowing the excretion of gastrointestinal and
pancreatic juices.
In order to explain the mechanisms whereby gastric
bypass procedures are effective in normalizing glycemia,
it has been supposed that the gut removal itself may
have a main role in diabetes remission, also in light of
the fact that important hormones are secreted there. In
2009 Cummings reviewed the hypotheses that have been
considered so far to explain the mechanisms underlying
diabetes remission [18]. According to this Author, the
main hypotheses are the ghrelin hypothesis, the upper
intestinal hypothesis and the lower intestinal hypothesis.
The ghrelin hypothesis [18] maintains that ghrelin
regulation might be disturbed following RYGB. Ghrelinis a hormone secreted by the stomach and proximal
small bowel especially before meals, whose main physio-
logical effects are increased appetite and fat mass in-
crease [19]. In support of the ghrelin hypothesis, several
studies have shown that ghrelin levels after RYGB are
very low. Diminished ghrelin secretion can decrease ap-
petite and food intake, and its compromised secretion
might have a role in increasing glucose tolerance, as
ghrelin can stimulate counter-regulatory hormones [20].
The lower intestinal hypothesis claims that intestinal
shortcuts, created by bariatric surgery, expedite delivery
of ingested nutrients and increase Glucagon-like pep-
tide-1 (GLP-1) release. GLP-1 is an incretin, a peptide
secreted from enteroendocrine L-cells, which are found
throughout the small intestine and in high density in the
ileum. GLP-1 increases insulin secretion and it has also
been shown to increase proliferation and decrease apop-
tosis of beta-cells [21]. Both RYGB and BPD create gas-
tro-intestinal shortcuts and it has been shown that
postprandial GLP-1 secretion is increased post-surgery
[22,23]. It thus seems reasonable that after surgery
GLP-1 secretion may be enhanced, thus leading to
enhanced insulin secretion. This mechanism could per-
haps also explain the increase in β-cell mass that is
thought to accompany post-RYGB hyperinsulinemic
hypoglycemia [24].
The upper intestinal hypothesis maintains that avoid-
ing the contact of nutrients with the duodenum is some-
how the key process through which diabetes is
improved. The suggestion at the basis of this hypothesis
is that some kind of unknown factors or processes from
the duodenum would influence glucose homeostasis
[18]. The first support to this hypothesis came from
Rubino and Marescaux [25], who experimented a variant
of RYGB creating the intestinal bypass but leaving the
stomach intact, thus inducing the same digestive discon-
tinuity without reanastomosis. This surgery, called duo-
denal–jejunal bypass (DJB), was tested in several studies
that showed an improvement in T2DM with no reduc-
tion in body weight [20,26-30]. These studies suggest
that the exclusion of the proximal intestine per se has a
role in diabetes remission.
In the present work, we introduce a mathematical
model, which approximately describes the dynamics of
the glucose-insulin-incretins system, allowing for the
reproduction of the known and putative effects of baria-
tric surgery on insulin secretion. The three hypotheses
advanced by Cummings [18] correspond to three specific
scenarios obtainable by assigning suitable values to the
model parameters. In this way it is possible to theoretic-
ally investigate the effects of the hypothesized mechan-
isms and verify whether they are compatible, at least
qualitatively, with the known physiology in this class of
patients.
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Physiological meaning of the State Variables
Glucose in Stomach, Duodenum , Ileum and Plasma
(S, D, L, G)
Once ingested, glucose goes into the stomach, where di-
gestion begins, and then reaches the small bowel, pas-
sing through the pylorus. The small intestine is divided
in duodenum, jejunum and ileum, which may also be
divided into subsections [31]. In the proposed model we
consider a simplified division in duodenum and ileum.
Each section is composed of different types of cells,
which secrete different peptides in response to the pas-
sage of nutrients, and glucose is absorbed into plasma
from each section, with different absorption rates. In our
model the amount of glucose present in each section is
considered as a state variable, in order to simulate the
effect of secreted peptides and of the absence of a gut
portion after surgery.
Plasma Insulin (I)
Insulin is a hormone secreted from pancreatic beta-cells in
response to rising levels of plasma glucose concentrations.
Insulin’s main function is to stimulate peripheral-tissue
glucose uptake and inhibit liver glucose production. When
insulin function is compromised, either depending on a de-
fect in the action of insulin on tissues, or on a defect of
insulin production itself, glucose is insufficiently absorbed
by tissues or is excessively produced by the liver.
Incretins: GLP-1 (W) and GIP (U)
Glucagon-like peptide 1 (GLP-1) is an incretin, it stimu-
lates insulin biosynthesis and insulin secretion in a
glucose-dependent manner. The enteroendocrine L-cells
of the distal ileum and colon synthesize and secrete
GLP-1 in response to nutrient ingestion. There might be
endocrine and neural signals accounting for the rapid
increase of plasma GLP-1 after a meal, which happens
before digested food has transited through the gut and
has been in proximity with the L-cells. GLP-1 is synthe-
sized as an inactive molecule of 37 amino acids; the six
N-terminal ones are then cleaved yielding the active
form. GLP-1 plasma concentrations are low in the
fasting state, they increase 5 to 15 minutes after the
meal. The circulation half-life for GLP-1 is only 1–2
minutes, since it is rapidly degraded by the enzyme
Dipeptidyl-peptidase IV (DPP4, see below). Once in the
bloodstream, GLP-1 reaches its target cells, which are
pancreatic alfa and beta-cells, but also cells from other
tissues (the nervous system, heart, kidney, lung, gastro-
intestinal tract) [32]. Insulin release is highly correlated
with the secretion of GLP-1, which is one of the stron-
gest known insulin stimulating factors [33].
Glucose Insulinotropic Polypeptide (GIP) is another
incretin, secreted from K-cells, which are found inhighest density in the duodenum and proximal jejunum,
but have actually been found in the whole small bowel
mucosa [33]. Glucose and fat absorption are the main fac-
tors stimulating secretion of GIP, which is produced as an
active 42 aminoacid peptide. Similarly to GLP-1, plasma
concentrations increase 5 to 15 minutes after the meal, and
the polypeptide is then cleaved by DPP4. GIP circulation
half-life is 5–7 minutes. When GIP is released from the gut
into the bloodstream, it reaches its specific receptors on
pancreatic beta-cells. Some GIP receptors are also found on
the adipose, bone and brain tissues. In the beta-cell, GIP
induces an increase in cAMP concentration, which causes
an elevation in calcium, thus triggering the release of insu-
lin granules [32,33].
The action of GLP-1 and GIP has been named the
“incretin effect” [34]: it refers to the post-meal increase
in insulin secretion due to these gut-secreted hormones.
In healthy subjects this effect accounts for 50-70% of the
overall insulin response [34]. In T2DM patients the
“incretin effect” is reduced and this may depend on a de-
fect in GLP-1 and GIP secretion [35].DPP4 (P)
Dipeptidyl-peptidase IV (DPP4) is a ubiquitous serine
protease which rapidly degrades GIP and GLP-1 as well
as many other peptides. Its role in the inactivation of
bioactive peptides was recognized due to its unique abil-
ity to liberate Xaa–Pro or Xaa–Ala dipeptides from the
N-terminus of regulatory peptides. DPP4 has several
functions and is strongly expressed on the surface of
cells of different kinds of tissues: gastrointestinal tract,
exocrine pancreas, kidneys, biliary tract, lymphoid
organs, various glands. It is also found in body fluids
such as blood plasma. DPP4 can inactivate many mam-
malian regulatory peptides, such as neuropeptides, circu-
lating hormones and chemokines. Some important DPP4
substrates are neuropeptide Y, endomorphin, peptide YY,
growth hormone-releasing hormone, GLP-1 and −2, and
GIP [36].Anti-incretin (A)
The upper intestinal hypothesis implies the presence of
some kind of unknown “factor” which is compromised
after the exclusion of the duodenum from the GI tract.
This factor would be lowering or antagonizing the effect
of incretins, so that the exclusion of the duodenum and
the consequent impairment of the anti-incretin would
lead to an increase in insulin secretion [37]. In order to
simulate this hypothesis we included in the model a vari-
able for the “anti-incretin” plasma concentration, assum-
ing that the “anti-incretin” is secreted from the
duodenum and inhibits the release of incretins.
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Ghrelin is a 28 amino acid hormone secreted by the stom-
ach and proximal small bowel. Its main physiological effects
are orexigenia (increased appetite) and fat mass increase.
Ghrelin is a strong stimulator of growth hormone (GH)
release, being the natural ligand of the GH secretagogue
receptor. Nevertheless, it has been shown that ghrelin has
several different activities (stimulation of lactotroph and
corticotroph secretion, cardiovascular actions, antiprolifera-
tive effect on thyroid and breast tumors, gastric motility
and acid secretion regulation through vagal mediation) [19].
Plasma ghrelin concentration increases progressively before
a meal, during which it varies by two- to threefold, reaching
a minimum about one hour after the meal: this suggests
that it may have a role in sensing low blood glucose. More-
over, it has been shown that ghrelin is produced (at a low
rate) from the pancreas, which may indicate some relation
with insulin release. Taken together, these findings lead to
the involvement of ghrelin in glucose homeostasis and in
diabetes development. In recent years the role of ghrelin
has been widely investigated and, even if the mechanisms
of action are still not completely clear, progress has been
made [38]. A number of studies in vitro and in vivo show
that ghrelin induces hyperglycemia and reduces insulin se-
cretion, but some results are controversial and it is not clear
whether the decrement in insulin production is a conse-
quence of a direct effect of ghrelin on pancreatic beta-cells.
A recent human study in vivo by Tong et al. [39] shows
that exogenous ghrelin has an inhibitory effect on glucose-
stimulated insulin release and glucose disappearance.The model
The proposed model is composed of 10 ordinary differ-
ential equations: the physiological meaning of each vari-
able has been described above and in Figure 1 a block
diagram representing the model is shown.
dS tð Þ
dt
¼ kdsS tð Þ  klsS tð Þ þ
XNmeals
i¼1




¼ kdsS tð Þ  kldD tð Þ  kgdD tð Þ; D Tminð Þ ¼ DTmin ð2Þ
dL tð Þ
dt




¼ kxgGðtÞ  kxgiIðtÞGðtÞ þ f kgdDðtÞþkglLðtÞVg
þkliverg ;G Tminð Þ ¼ GTmin
ð4ÞdI tð Þ
dt
¼ ðkigG tð Þ þ kiwgG tð ÞW tð Þeλ01aA tð Þ
þ kiugG tð ÞU tð Þeλ02aA tð ÞÞeλ03hH tð Þ




¼ kwdD tð Þe−λ04aA tð Þ þ kwlL tð Þ−kxwpP tð ÞW tð Þ




¼ kudD tð Þeλ05aA tð Þ þ kulL tð Þ  kxupP tð ÞU tð Þ




¼ kp  kxpP tð Þ; P Tminð Þ ¼ PTmin ð8Þ
dA tð Þ
dt




¼ kh06eλ06sS tð Þ þ kh07eλ07dD tð Þ þ kh08eλ08lL tð Þ
 
eλ09iI tð Þ
kxhH tð Þ; H Tminð Þ ¼ HTmin
ð10Þ
Equation 1 describes the dynamics of the amount of
ingested glucose in the stomach, the first term repre-
sents the transfer from the stomach to the duodenum,
the second the transfer from the stomach to the ileum,
which happens in case of duodenum removal. The last
term is a summation representing the entry of glucose
with a Dirac delta, three times a day, corresponding to
three meals.
Equation 2 describes the dynamics of the amount of
glucose in the duodenum. The first term represents the
entry from the stomach, the second is the exit to the
ileum, and the last term is the absorption to the plas-
matic glucose compartment.
Equation 3 describes the variation of the amount of
glucose in the ileum. The entry terms, represented by
the first two terms, are from the duodenum or from the
stomach in case of bypass surgery, respectively. The last
term accounts for the absorption into the plasmatic
compartment.
Plasma glucose concentration dynamics is described in
equation 4: the first two terms represent the insulin-in-
dependent and insulin-dependent glucose tissue uptake,
respectively. The third term is plasma glucose entry.
This is written as proportional to a fraction (not all of








































Figure 1 Model block diagram. State variables are represented with circles, solid arrows represent mass transfers, while dashed arrows indicate
stimulations. The model is here schematically represented: the path of ingested glucose (Mi) from the stomach (S) through duodenum (D) and
ileum (L), and absorption in the plasmatic compartment (G) is along the central set of compartments (bottom-down). The insulin compartment (I)
is on the bottom right of the figure, while the incretins (W and U) and DPP4 (P) are represented in between glucose compartments and insulin.
Finally, on the left side, anti-incretin (A) and ghrelin (H) are represented. All the compartments are linked with dashed arrows, indicating
stimulation of the entry rates or of the elimination rates, showing the relationship between state variables.
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The term is divided by the glucose distribution volume.
Equation 5 represents plasma insulin concentration.
All the entry terms are collected in parentheses: the first
term accounts for glucose dependent insulin secretion.
The second and third terms depend on glucose as well,
but also on GLP-1 and GIP concentration, respectively.
GLP-1 and GIP action is opposed by anti-incretin with
an exponentially decreasing dynamics. All insulin entry
terms decrease exponentially with ghrelin concentration.
The last term accounts for linear insulin elimination. Al-
though in the literature the dependency of incretin-
dependent insulin secretion from plasma glucose con-
centration is not always considered [40], there is indeed
evidence supporting this mechanism. As from Verspohl
2009 p.117-118 “. . .activation of GIP and GLP-1 recep-
tors on B-cells leads to rapid increases in levels of cAMP
(Fig. 5 in Verspohl 2009) which is glucose-dependent
(Drucker et al., 1987) and which is linked to both acute
and long-term effects” [41,42]. Recent publications also
report this effect, for example, in the paper from Gautier
et al. 2008, it is stated: “GIP exerts glucose-dependent
stimulatory effects on insulin secretion in animals and
humans” and “GLP-1 stimulates glucose-induced insulin
secretion in isolated islets of Langerhans” [43]. The same
effect is reported from Holst [44,45].The next equations describe the dynamics of those
factors, mentioned above, which can influence glucose
and insulin homeostasis. Equation 6 describes the vari-
ation of plasma GLP-1 concentration. The first term
accounts for the entry due to the passage of glucose
into the duodenum, which is exponentially controlled
by anti-incretin concentrations. The second term
represents the entry due to glucose in the ileum. The
third is the elimination term representing DPP4 action,
the fourth accounts for the natural GLP-1 disappear-
ance. The last term accounts for GLP-1 constant
secretion.
Equation 7 is similar to equation 6, and describes GIP
dynamics.
In equation 8 DPP4 dynamics is represented. This has
been supposed to be simple, that is, a constant produc-
tion and a linear elimination. DPP4 is an ubiquitous en-
zyme involved in many pathways, thus it would be very
complex and somewhat arbitrary to describe a more
detailed control mechanism for it.
The anti-incretin equation (Eq. 9) is composed of the
entry due to glucose in the duodenum, a linear elimin-
ation term, and a constant production rate.
The last equation (Eq. 10) describes ghrelin concentra-
tion variation. The first three terms, in parentheses, repre-
sent the constant entry terms which are exponentially
Toghaw et al. Theoretical Biology and Medical Modelling 2012, 9:16 Page 6 of 15
http://www.tbiomed.com/content/9/1/16inhibited by the presence of glucose in the stomach, in the
duodenum and in the ileum, respectively. All entry terms
are also exponentially decreased by insulin concentration.
The last term accounts for linear ghrelin elimination.
Parameter values
Model parameters, which are not determined from
steady state assumptions or other constraints, have been
given as reasonable a value as possible, based on the
literature. Simulations start at time Tmin = 0 minutes, at
which we assume an early morning fasting state,
therefore there is no glucose in the stomach, duodenum
or ileum. Therefore, at time Tmin we have STmin =
DTmin = LTmin = 0 mmol. Meal times have been set to
t1 = 30 min, t2 = 300 min, t3 = 540 min, corresponding to
breakfast, lunch and dinner, respectively. The amount of
ingested glucose at each meal is, respectively,
M1 = 400 mmol, M2 = 500 mmol, M3 = 600 mmol. In this
work we will show simulations for only one meal
(e.g. lunch).
Since bariatric surgery is performed on obese subjects,
we considered, where possible, parameters values
corresponding to this category of patients.
Fasting plasma glucose was reported to be
8.05 ± 1.82 mM for T2DM obese subjects [46]. American
Diabetes Association guidelines define the diabetes
threshold at 7 mM fasting plasma glucose [47], while
impaired fasting glucose is defined above 6.1 mM. In the
present work we choose to represent a borderline dia-
betic obese subject with GTmin = 7 mM.
In obese subjects, fasting plasma insulin was found
to be 171 ± 74 pM, corresponding to subjects
with 8.05 ± 1.82 mM glycemia [46]. Here we consider
ITmin = 100 pM.
Fasting plasma GLP-1 levels were reported at 8.7 ± 2.8
pM for obese subjects [48], we set WTmin =8 pM. From
the same source fasting plasma GIP levels were
21.5 ± 5.8 pM for normal and obese subjects [48,49], we
set therefore UTmin =20 pM.
Mean DPP4 activity in human serum was found to be
29.7 ± 6.6 U/l as collected from 481 healthy adult volun-
teers (ages 19–61 years) [50], so we set PTmin = 30 U/l.
The maximum level of GLP-1 plasma concentration,
after glucose ingestion, in obese patients, after Roux-en-
Y gastric bypass surgery is Wmax = 100 pM [46]. For what
concerns GIP maximal concentration, we set Umax = 300
pM, as GIP secretion is greatly increased (10 to 20-fold)
in response to meal ingestion, so we consider 15 times
the basal plasma concentration [33]. Pmax is taken arbi-
trarily as 10 times Pb that is Pmax = 300 U/l.
Dmax and Lmax are the maximal glucose content in the
duodenum and in the ileum, respectively, during the
course of normal food intake. We set them to
2000 mmol, corresponding to 360 grams of glucose.Glucose distribution volume is approximately 0.2 l/kg
body weight [51]. Hypothesizing for moderate obese
subjects an average weight of 90 kg, we set VG= 18
liters.
Stomach emptying rate is represented from the param-
eter kds which we set at 0.02 min
-1, as found in the lit-
erature [52] and kls was set to the same value. Similarly,
the transfer rates from the duodenum to the ileum kld,
from the ileum to plasma kgl, and from duodenum to
plasma kgd, were set to 0.02 min
-1.
Silber et al, [53] report a glucose clearance rate
(CL) = 0.089 l/min, with kxg =Cl/VG is approximately
equal to 0.0049 min-1. Insulin-dependent glucose elimin-
ation rate, kxgi, has been set to 0.2 × 10
-4 as from [54],
again consistent with a degree of insulin resistance typic-
ally exhibited by obese prediabetics. The fraction of
absorbed glucose was set to f = 0.9.
The parameter kgliver was determined by setting the
derivative of equation (4) equal to zero (steady state):
0 ¼ kxgGTmin  kxgiITminGTmin þ kgliver;
thus
kgliver ¼ kxgGTmin þ kxgiITminGTmin ¼ 0:077pM=min
The disappearance rate constant for insulin has been
set to kxi = 0.04 min
-1 [55].
The combined action of GLP-1 and GIP is estimated
to account for approximately 50%–70% of the total insu-
lin secretory response depending on the size of the glu-
cose load ([44,56-58]). GLP-1 was reported to be three
to five times more potent than GIP ([33,56,59]).
Therefore, kig, kiwg and kiug were determined by setting
the derivative of equation (5) equal to zero (steady state)
0 ¼ ðkigGT min þ kiwgGT minWT mineλ01aAT min
þkiugGT minUT mineλ02aAT minÞeλ03hHT minkxiIT min
and from the stated hypotheses
kigGT min ¼ 0:3 fkigGT min þ kiwgGT minWT mineλ01aAT min
þkiugGT minUT mineλ02aAT ming
Solving equations we have
kig ¼ 37 kiwgWT mine
λ01aAT min þ kiugUT mineλ02aAT min
 
kiwg ¼ 0:56kxiIT minGT minWT mine λ01aAT minþλ03hHT minð Þ




These parameter values change according to the differ-
ent scenario set to simulate the three hypothesis.
Toghaw et al. Theoretical Biology and Medical Modelling 2012, 9:16 Page 7 of 15
http://www.tbiomed.com/content/9/1/16The incretin effect has been shown to be reduced in
patients with type 2 diabetes, although the mechanisms
are still incompletely understood [43].
The parameter lambda01a represents the decay rate of the
GLP-1 effect of insulin production, due to the anti-incretin
effect. Since insulin secretion in response to GLP-1 in dia-
betic patients has been shown to be similar to that in nor-
mal subjects [5], we set A501 (anti-incretin concentration at
which GLP-1 effect is half of its maximum value) to 150
pM, consequently lambda01a = log(2)/A501 =0.002 pM
-1.
lambda02a is the decay rate of GIP stimulated insulin
production due to the increase in anti-incretin concen-
tration. Since insulin secretion in response to GIP ad-
ministration has been found to be 54 % lower in diabetic
patients [43], we set A502 (anti-incretin concentration at
which GIP effect is half of its maximum value) to 75 pM
and lambda02a = log(2)/A502 = 0.004 pM
-1.
lambda03h represents the decay rate of insulin production
due to the increase in ghrelin concentration. In Tassone
et al. (Figure 2 page 548 [60]) insulin levels reductions after
ghrelin administration in obese humans are reported
(ghrelin 1 μg/kg). Taking H50= 1225 pM we obtain lamb-
da03h = log(2)/H50 = 2.46 x 10
-4 pM-1.
GLP-1 is secreted from intestinal endocrine L-cells,
which can be found throughout the human small intes-
tine with highest density in the distal ileum. Mortensen
et al. [61] showed that the percentage of GLP-1 immu-
noreactive cells increases along the length of the gastro-
intestinal tract. From Figure 2 in Mortensen’s paper [61],
the density of GLP-1 immunoreactive cells is about 15 %
of the total amount of endocrine cells in the distal duo-
denum or proximal jejunum, and about 45% in the
whole ileum. This approximate ratio is also consistent
with median and maximum GLP-1 intestinal wall con-
centrations reported in the same paper [61].
We therefore assume that kwd , the release rate of
GLP-1 per mmol of ingested glucose appearing in
the duodenum and the jejunum, is approximately 1/
3 of the release rate of GLP-1 per mmol of ingested
glucose appearing in the ileum: kwd = kwl/3.
We hypothesize that, in a long simulation of GLP-1
dynamics, with a very large amount of glucose both in
the duodenum and in the ileum (say, 2 moles or 360
grams), a steady state would be reached, so that GLP-1
production would equal GLP-1 elimination:
kwd2000þ kwl2000 ¼ KxwpPmaxWmax
In the light of the above proportion between duodeno-
jejunal and ileal contributions to GLP-1 secretion we
can write
1=3ð Þkwl2000þ kwl2000 ¼ kxwpPmaxWmax;where Pmax = 300 U/l is the maximal concentration of
DPP4 and Wmax = 100 pM the maximal concentration of
GLP-1, and kxwp = 9.04x10
-4 min-1/pM the GLP-1 elim-
ination rate. The ileal incretin secretion would thus be
kwl = 0.0102 pM/min/mmol, and the corresponding duo-
deno-jejunal GLP-1 secretion kwd = 0.0034 pM/min/
mmol. These are indeed very rough estimates. However,
model behavior is affected very little by variations of
these secretory rates from 20% to 300% of these pre-
sumptive amounts.
The parameter lambda04a [pM
-1] is the decay rate of
GLP-1 production due to the anti-incretin. Since the se-
cretion of GLP-1 in diabetic patients is impaired, we set
A502 = 75 pM, we thus have lambda04a = log(2)/
A502 = 0.00602 pM
-1.
Plasma half-life of GLP-1 is around 2.3 minutes (from
table 2 in Meier’s paper [62]). Since GLP-1 is mainly
degraded by the enzyme DPP4 (reviewed from Deacon
[63]), we assume that kxwp, the disappearance rate con-
stant for GLP-1 due to DPP4, is approximately 90% of
the disappearance rate constant for GLP-1. This hypo-
thetical value is computed as kxwp Pmax = 0.9log(2)/2.3,
and kxwp = 9.04x10
-4 min-1/pM . While kxw, the dis-
appearance rate constant for GLP-1, is kxw = 0.1log(2)/
2.3 = 0.0301 min-1.
kw was determined by setting the derivative of equation
(6) equal to zero (steady state), thus kw=0.4581pM/min.
GIP is secreted from intestinal K-cells, which can be
found throughout human small intestine. The highest
percentage of GIP-immunoreactive cells is however in
the upper jejunum [61]. From Figure 2 in Mortensen’s
paper [61], the density of GIP immunoreactive cells is
about 20 % of the total amount of endocrine cells in the
distal duodenum or proximal jejunum, and about 10 %
in the whole ileum. This approximate ratio is also con-
sistent with median and maximum GLP-1 intestinal wall
concentrations, reported in the same paper [61].
We therefore assume that kud, the release rate of GIP
per mmol of glucose appearing in the duodenum and
the jejunum, is approximately twice the rate of release of
GIP per mmol of glucose appearing in the ileum. The
value was computed as kud = 2kul.
As it was computed for GLP-1, we set at 2 moles the
maximum plausible glucose amount in the duodenum
and in the ileum, and we hypothesize to reach a steady
state where
kud2000þ kul2000 ¼ kxupPmaxUmax
or, from the above proportion between duodeno-jejunal
and ileal contributions to GIP secretion,
2kul2000þ kul2000 ¼ kxupPmaxUmax;



















































































Figure 2 Model simulation. Thick gray line: pre-surgery case; solid line: lower-intestinal hypothesis (LIH); dash-dot line: anti-incretin hypothesis
(AIH); dashed line: ghrelin hypothesis (GH). 2.1 Stomach glucose content is unchanged in all the hypotheses. 2.2 Glucose content in the
duodenum is zero in the LIH, while is unchanged in the other scenarios. 2.3 Ileum glucose content is higher and the peak is earlier, compared to
the pre-surgery scenario, for the LIH. In the other hypotheses the dynamics is the same. 2.4 Plasma glucose concentration is lower in the AIH and
the LIH (more markedly in the latter). The curve in the GH is unchanged compared to the pre-surgery case. 2.5 Plasma insulin concentration is
higher in the AIH and the LIH (more markedly in the latter). GH is unchanged compared to the pre-surgery case. 2.6 GLP-1 concentration is
markedly higher in the LIH, while is slightly higher in the AIH and unchanged in the GH. 2.7 GIP concentration increases in the AIH, decreases in
the LIH, is unchanged in the GH. 2.8 Anti-incretin concentration is constant at the basal value in the LIH, zero in the AIH, unchanged in the GH
2.9 Ghrelin concentration dynamics is slightly lower in the LIH and the AIH, while for the GH ghrelin concentration is zero.
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x10-4 min-1/pM. So we have kul = 0.0104 pM/min/mmol
and kud = 0.0208 pM/min/mmol.
The parameter lambda05a [pM
-1] is the decay rate of
GIP production as anti-incretin concentrations increase.
Since it has been shown that GIP measurements in dia-
betic subjects are the same compared to patients with
no T2DM [5] we take A501 = 150 pM, obtaining lamb-
da05a = log(2)/A501 = 0.0046 pM
-1.
Plasma half-life of GIP is around 5 minutes, from
table 2 in Meier’s paper [62]. Similarly to GLP-1,
GIP is mainly degraded by the enzyme DPP4
(reviewed from Deacon [63]). We therefore assume
that kxup, the disappearance rate constant for GIP
due to DPP4, is approximately 90% of the disappear-
ance rate constant for GIP. A plausible value for
kxup can therefore be computed from kxupPmax = 0.9
log(2)/5, so that kxup =4.16x10
-4 min-1/pM. The par-
ameter kxu, the disappearance rate constant for GIP,
was computed as kxu =0.1log(2)/5 = 0.0139 min
-1.
The parameter ku was determined by setting the de-
rivative of equation (6) equal to zero (steady state), thus
obtaining ku = 0.5268pM/min.
The enzyme DPP4 is responsible for the rapid deg-
radation of the incretin hormones. From Figure 1 inMentlein’s paper [36], DPP4 is found on the plasma
membrane of cells at numerous sites, including the
kidney, brush-border membranes of the intestine,
and the liver. It is also located on the endothelial
cells of blood vessels and is found in a soluble form
in plasma. Since the factors regulating the expression
and activity of DPP4 in glucose metabolism are
barely known, and since the action of DPP4 is ubi-
quitous and its role affects many different substrates,
we assume that DPP4 levels are approximately
constant.
The parameter kp, the appearance rate constant
for DPP4, is determined by setting the derivative of
equation (8) equal to zero (steady state) and kxp, the dis-
appearance rate constant for DPP4, is taken arbitrarily
as 0.05 min-1:
kp ¼ kxpPTmin ¼ 1:5U=L=min:
We arbitrarily set the unit of measurement of the un-
known anti-incretin hormone to pM. We suppose that
fasting and maximum plasma Anti-incretin level are
the same as GIP: ATmin = 25 pM and Amax = 500 pM. We
assume the disappearance rate constant the anti-incretin,
kxa = 0.05 min
-1, as DPP4. kad and the appearance rate
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by taking analogy with DPP4, as kadDmax ¼
kxaAmax; from which kad ¼ 0:0125pM=min=mmol.
Fasting plasma ghrelin has been found to be around
148 ± 30 pM for obese subjects [64], so we set HTmin =
150 pM. From the same reference Hmax =300 pM, and
the approximate minimum level of plasma ghrelin col-
lected from obese patients after gastric bypass surgery
Hmin = 29.6 pM [64].
Plasma ghrelin concentrations rise gradually in the
fasted state and decrease immediately after a meal (re-
view by Hameed et al. [65]). Plasma ghrelin concentra-
tions decrease after oral and intravenous administration
of glucose [66]. However, the percentage of ghrelin de-
crease was found to be inversely correlated with the per-
centage of increase in insulin and glucose [67]. The
tissue content of immunoreactive ghrelin in the rat was
found to be around 90 % in the stomach, 7 % in the duo-
denum-jejunum and 2 % in the ileum [68]. Plasma ghre-
lin levels from subjects who underwent gastric bypass
decreased to around 1/5 the pre-surgery levels [64], sug-
gesting that around two thirds of circulating human
ghrelin come from the stomach and one third comes
from the small intestine.
The parameters kh06, kh07 and kh08, the appearance
rate constants for ghrelin due to glucose in the stomach,
duodenum and ileum, respectively, were determined by
setting the derivative of equation (10) equal to zero
(steady state):
0 ¼ kh06 þ kh07 þ kh08ð Þeλ09iItmin  kxhHtmin
kh06 þ kh07 þ kh08 ¼ kxhHtmineλ09iItmin
kh06 ¼ 2=3ð ÞkxhHtmineλ09iItmin
kh07 ¼ 2=9ð ÞkxhHtmineλ09iItmin
and
kh08 ¼ 1=9ÞkxhHtmineλ09i Itmin

where kxh is the disappearance rate constant for ghrelin,
arbitrarily taken as 0.02 min-1. These parameters change
according to the scenario.
We have no direct information on the decay rate of
ghrelin production with increasing glucose in the stom-
ach, the duodenum or ileum. Since plasma ghrelin con-
centrations decrease immediately after a meal and
considering the 24-hour plasma ghrelin profiles from
Figure 1 in Cumming’s paper [64], S50, D50 and L50 were
taken as 50, 100 and 150 mmol, respectively, in order to
match the reported plasma ghrelin profiles.
The parameter lambda06s [mmol
-1] is the decay rate of
ghrelin production as amounts of glucose in the stomachgrow larger. Taking S50 = 50 mmol we have lambda06s =
log(2)/S50 = 0.006 mmol
-1.
The parameter lambda07d [mmol
-1] is the decay rate of
ghrelin production as amounts of glucose in the duode-
num grow larger. Taking D50 = 100 mmol we have lamb-
da07d = log(2)/D50 = 0.003 mmol
-1.
The parameter lambda08l [mmol
-1] is the decay rate of
ghrelin production as amount of glucose in the ileum
grow larger. Taking L50 = 150 mmol we have lambda08l =
log(2)/L50 = 0.002 mmol
-1.
The parameter lambda09i [pM
-1] is the decay rate of
ghrelin production as plasma insulin concentrations in-
crease. Taking I50 = 10 pM we have lambda09i = log(2)/
I50 = 0.03 pM-1.
Three scenarios
The present model was implemented in Matlab2010bW
and four simulations were compared. One represents
the pre-surgery scenario, in which no parameters are
changed in the model: meals are administered and all
parameters are fixed to the values shown above.
In order to simulate the three hypotheses, the para-
meters that were thought to differ from the pre-surgery
situation were changed on the basis of the hypothesized
physiological mechanism. In Table 1 all parameter values
that were changed to test the three hypotheses are
shown.
It must be remarked that the simulations conducted in
this way reflect “pure” or isolated effects of each of the
three hypothesized mechanisms.
The ghrelin hypothesis
This hypothesis is based on the observation that plasma
ghrelin levels decrease to about one third of the pre-sur-
gery concentration in subjects who undergo a proximal
Roux-en-Y gastric bypass [64]. Since Ghrelin is shown to
suppress insulin secretion [67] this could be the mech-
anism at the basis of diabetes remission.
To test this hypothesis with the model, ghrelin was
excluded from the model, without in any way affecting
glucose transit in the gut compared to pre-surgery. To
exclude ghrelin we set the following parameters to 0:
plasmatic ghrelin basal level, HTmin = 0, maximum
amount of ghrelin, Hmax = 0, and minimum amount of
ghrelin, Hmin = 0.
The lower intestinal hypothesis
It is hypothesized that GLP-1 secretion is increased after
bariatric operations, which create intestinal shortcuts
and expedite delivery of ingested nutrients to the lower
bowel.
For the test model, the duodenum has been excluded
from contact with nutrients: glucose goes directly from
the stomach to the ileum.




Parameters Lower-intestinal (GLP-1) Upper-intestinal (Anti-incretin) Ghrelin
Nmeals 1 1 1 1 meal n.1 is simulated
M1 500 500 500 500 amount of glucose in the meal
ATmin 25 25 0 25 plasmatic anti-incretin basal level
Amax 500 500 0 500 maximum amount of anti-incretin
HTmin 150 150 150 0 plasmatic ghrelin basal level
Hmax 300 300 300 0 maximum amount of ghrelin
Hmin 29.6 29.6 29.6 0 minimum amount of ghrelin
kds 0.02 0 0.02 0.02 transfer rate from stomach to duodenum
kls 0 0.02 0 0 transfer rate from stomach to ileum
kld 0.02 0 0.02 0.02 transfer rate from duodenum to ileum
kgd 0.02 0 0.02 0.02 transfer rate from duodenum to plasma glucose
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the stomach to the duodenum, from the duodenum to
the ileum and from the duodenum to plasma glucose,
were set to 0: kds = 0, kld = 0, kgd = 0. The transfer rate
from stomach to ileum was set to a value different from
0, compared to pre-surgery: kls = 0.02.
The upper intestinal hypothesis
Under this hypothesis it is claimed that the exclusion of
a short segment of proximal small intestine (primarily
the duodenum) from contact with ingested nutrients
exerts direct anti-diabetic effects, by means of the reduc-
tion in some unknown anti-incretin molecule secreted
by the duodenum itself.
To test this hypothesis the Anti-incretin was excluded
from the model, without affecting glucose transit in the
gut.
The following parameters have been changed, com-
pared to pre-surgery: the plasmatic anti-incretin basal




The model has been run setting first the parameters to
the “default” pre-surgery situation, and then to the three
scenarios representing the three hypotheses. The corre-
sponding state variable plots are shown in Figure 2. The
model has been formalized in order to simulate three
meals in one day but only the first meal is shown here
for clarity. In Figure 2 the 4 scenarios are shown together
(thick gray line for the pre-surgery case, solid line for
the lower-intestinal hypothesis, dash-dot line for the anti-
incretin hypothesis, dashed line for the ghrelin hypothesis,).The DPP4 plot has not been shown because the concentra-
tion is constant, as explained in the Model section.
In the lower-intestinal hypothesis (solid line) glucose is
transferred directly to the ileum, so glucose content in
the duodenum is zero, while glucose content in the
ileum is comparable to the glucose content in the duo-
denum pre-surgery curve. For the other two hypotheses
the curves remain the same as the pre-surgery case.
For plasma glucose concentration dynamics the peak
is lower and elimination is faster for the anti-incretin hy-
pothesis and even more so for the lower-intestinal hy-
pothesis. Symmetrically, plasma insulin concentration is
higher and with a quicker dynamics in the anti-incretin
hypothesis and even more so for the lower-intestinal hy-
pothesis. GLP-1 concentration is slightly higher in the
anti-incretin scenario, while it is remarkably elevated in the
lower-intestinal hypothesis, compared to the pre-surgery
situation. GIP concentration is higher than pre-surgery for
the anti-incretin scenario and lower than pre-surgery for
the lower-intestinal scenario. Anti-incretin concentration is
0 for the anti-incretin hypothesis, as it was set from the
parameters, while in the lower-intestinal hypothesis con-
centration is constant. Ghrelin concentration is zero for
the ghrelin scenario, while it does not change appreciably
among the remaining three scenarios. It must be noticed
that for every state variable, excepting ghrelin concentra-
tion itself, the pre-surgery and ghrelin scenarios produce
essentially undistinguishable curves.
Discussion
In 1995 Poires et al. first reported that the diabetes reso-
lution effect observed after RYGB was remarkable (82.9%)
[69,70]. Subsequently there have been several studies
reporting that amelioration in insulin resistance was
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study reported in Chiellini et al. 2009 showed that BPD on
T2DM patients with BMI <35 kg/m2 achieved reduced gly-
caemia and an increase in insulin sensitivity one month
post-surgery [71]. Observations from a study conducted by
Hickey et al. showed an improvement in glucose and insu-
lin levels few days after gastric bypass surgery, before the
establishment of a significant weight loss [6]. Other studies
have shown that weight loss after bariatric surgery cannot
account for diabetes recovery [72,73]. The independency of
diabetes remission from weight loss has therefore been
recognized since the 90’s but the mechanisms by which this
happens are still under investigation [25,74-76].
Controversial results have in fact been reported on this
topic, with some Authors maintaining that diabetes im-
provement is not independent from weight loss. In the
study from Campos et al., comparing a group of patients
undergoing RYGB with a group of non operated subjects
[9], it was reported that peripheral glucose uptake im-
provement is observed only after significant weight loss.
Another trial, comparing DJB- and Sham-operated
rodents, suggested that DJB alone is not sufficient to im-
prove insulin sensitivity independently from weight loss
[77].
Nevertheless, a very recent publication [17], specif-
ically focused on this topic, strongly supports the ef-
ficacy of bariatric surgery in diabetes amelioration.
An unblinded randomized controlled trial was per-
formed on 60 patients undergoing either gastric by-
pass, biliopancreatic diversion or conventional
therapy. Study results show T2DM remission in 75%
and 95% of the gastric bypass and biliopancreatic di-
version groups, respectively. None of the patients
treated with conventional medical therapy showed
T2DM remission. To support the hypothesis of
weight-independent diabetes remission, no correl-
ation was found between normalization of fasting
glucose levels and weight loss in the bariatric sur-
gery groups, and remission (judged from complete
withdrawal of medication) took place within 15 days
of surgery.
In the light of the results supporting weight-loss-
independent diabetes remission, some hypotheses
have been made, such as the ghrelin hypothesis, the
anti-incretin, or “foregut” hypothesis, and the lower
intestinal, or “hindgut” hypothesis [18]. In the
present paper we propose a mathematical model,
which can simulate these three hypotheses to illus-
trate what kind of results could be expected from
quantitative analysis of the consequences of the cor-
responding assumptions.
From the plots in Figure 2 it is evident that the ghrelin
curve, in all plots, is essentially no different from the
pre-surgery curve. This suggests that, based on themodel simulation, the hypothesis that ghrelin is the re-
sponsible factor for the remission of T2DM post-surgery
is not convincing. Findings about ghrelin levels reported
in the literature are in fact inconsistent [76], and there is
some evidence that ghrelin levels are unchanged after
bariatric sugery [78].
The anti-incretin and the lower intestinal hypothesis
simulations both give higher plasma insulin concentra-
tion peaks as well as lower glycemic levels, although the
effect seems to be more evident in the lower intestinal
case.
It must be underscored that the results of a simu-
lation study, such as the present one, are dependent
on a number of assumptions, both in the simplifica-
tion of the model structure and in the assessment of
the model parameters. For this reason it would be
inappropriate to draw conclusions from modest
quantitative differences in predictions, and the some-
what greater effect on glycemia levels, produced in
the lower-intestinal scenario, should not be viewed
as supporting this hypothesis over the anti-incretin
one.
On the other hand, if we consider predictions of
gut hormone levels, GLP-1 and GIP, we notice that,
while in the anti-incretin hypothesis both hormone
levels increase, in the lower intestinal hypothesis
GLP-1 concentration increases, while GIP concentra-
tion decreases, compared to pre-surgery levels. This
last prediction is not a small quantitative change but
a rather clear-cut qualitative difference in behavior,
which, according to the model, follows from the
physiology modifications introduced by bariatric sur-
gery under the two different sets of hypotheses.
From literature sources, diverse results are reported about
GIP level changes after bariatric surgery. Several studies re-
port decreased levels of GIP post-surgery [23,79,80]. Other
studies report essentially no change in GIP post-surgery
[46,81]. Bose [5] explicitly states that there is no support
for increased fasting GIP levels after bariatric procedures.
Laferrere et al. [82] report transient increase in GIP levels
after GBP. Therefore, while the preponderance of evidence
would seem to favor a decrease of GIP levels post-surgery,
thereby providing support for the lower-intestinal hypoth-
esis, this conclusion does not seem to be definitively
established.
The present work presents several limitations, for
example the values of the variables at t = Tmin do
not change post surgery, while there might be a vari-
ation in some of these values caused by physical
rearrangements. One such issue (regarding insulin
basal value) is discussed below. Another aspect to
consider is that a meal is usually composed of pro-
teins and fats, not only of glucose, and these would
also be involved in driving several mechanism, for
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process which indeed temporarily affects patient
homeostasis, due to prolonged fasting and bed rest.
Some of the limitations of the model could be
improved with the collection of data, among which glu-
cose and insulin concentrations after a glucose test, as
well as incretin levels. This would go a long way towards
a more precise and reliable assessment of the several
model parameters.
Another aspect which is worth mentioning, regards
insulin levels post-surgery. In fact, in the simula-
tions, insulin concentrations increase under both
upper and lower intestinal hypotheses. From the lit-
erature, however, there is some evidence for insulin
decrease after BPD during the Oral Glucose Toler-
ance Test (OGTT). From [46], insulin concentration
and peak insulin during OGTT increase while fasting
insulin decreases around 25% after RYGB. From
Briatore 2008, fasting insulin decreases around 50%,
acute insulin response or early insulin secretion in-
crease, after BPD [83]. From Valverde 2005 fasting
insulin decreases 75%, insulin concentrations de-
crease but the incremental area in plasma insulin
concentration over the first 30 min of the OGTT
test was higher after BPD [84]. From Bose 2009, a
review of the effects of bariatric surgery, fasting in-
sulin decreases, while insulin sensitivity increases.
From the available evidence, fasting insulin decreases
by 25-70% 1–6 months after surgery: this is consist-
ent with a lower insulin secretion determined by
higher insulin sensitivity [5]. Under these conditions,
insulin concentrations will in general decrease over
the natural history of the patient after surgery. For
the present simulations, however, fasting insulin is
regarded as a constant, independently of the
hypothesized maneuver, thus reflecting the physi-
ology immediately before and immediately after sur-
gery. Under these assumptions, Itmin is the same
both before and after surgery; under both upper and
lower intestinal hypotheses the levels of incretin in-
crease; the insulin secretory response to glucose
increases; and insulin concentrations increase. If we
set Itmin post-surgery to around 50 % its pre-surgery
level then insulin concentrations will not appear to
increase overall.
It would be interesting to consider the relevance of
the phenomenon of “Transfer of Addiction”, which
has been observed post-bariatric surgery: compulsive
overeating can in fact be replaced with other com-
pulsive disorders, such gambling, drugs, alcoholism,
compulsive shopping and exercise. This phenomenon
has been thought to be connected with the Reward
Deficiency Syndrome (RDS), which is related to
dopamine receptor defects, and has been describedas a genetic disease [85]. It has been thought that,
in those subjects where “Transfer of Addiction” takes
place after bariatric surgery, obesity and thus com-
pulsive eating behavior could be a sort of defense
mechanism towards other addictions [86]. It is
known that insulin can affect dopamine receptors
and vice versa [87], the activity of the dopamine
transporter can in fact be increased by high insulin
levels {{96}}. These findings are relevant in the frame
of bariatric surgery outcomes and should be taken
into consideration in a future development of the
present work.
Conclusion
The mathematical modeling approach can be a useful
tool for a better understanding of the interplay of the
several mechanisms operating in the glucose-insulin-
incretin system. Model conclusions, based upon a set of
reasonable but necessarily incomplete assumptions on
parameter values, point to the measurement of post-sur-
gery changes in GIP levels as one discriminating factor
differentiating expected behavior under the lower intes-
tinal and anti-incretin hypotheses. The weight of evi-
dence accumulated so far would seem to support the
lower intestinal hypothesis over the anti-incretin hypoth-
esis, while ghrelin effect appears irrelevant for the rapid
normalization of diabetes after bariatric surgery.
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